Blanco JL - Search Results

1

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group. Mallolas J, et al. Among authors: blanco jl. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f. J Acquir Immune Defic Syndr. 2009. PMID: 19390327 Clinical Trial.

2

Short communication: reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy.

Miró O, López S, Martínez E, Rodríguez-Santiago B, Blanco JL, Milinkovic A, Miró JM, Nunes V, Casademont J, Gatell JM, Cardellach F. Miró O, et al. Among authors: blanco jl. AIDS Res Hum Retroviruses. 2003 Nov;19(11):1027-32. doi: 10.1089/088922203322588387. AIDS Res Hum Retroviruses. 2003. PMID: 14678610 Free article.

3

Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy.

Navarrete P, Morente V, García F, Alós L, Arnedo M, Plana M, Gil C, Caballero M, Miró JM, Martínez E, Fumero E, Castro P, Blanco JL, Mallolas J, Blanch JL, Cruceta A, Mestre G, Pumarola T, Gallart T, Gatell JM. Navarrete P, et al. Among authors: blanco jl. Antivir Ther. 2003 Dec;8(6):635-7. Antivir Ther. 2003. PMID: 14760898

4

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM. García F, et al. Among authors: blanco jl. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13. doi: 10.1097/00126334-200406010-00007. J Acquir Immune Defic Syndr. 2004. PMID: 15167289

5

Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.

Martínez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco JL, Larrousse M, Mallolas J, García F, Miró JM, Gatell JM. Martínez E, et al. Among authors: blanco jl. Lancet. 2004 Jul 3-9;364(9428):65-7. doi: 10.1016/S0140-6736(04)16591-4. Lancet. 2004. PMID: 15234858

6

Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study.

Biglia A, Blanco JL, Martínez E, Domingo P, Casamitjana R, Sambeat M, Milinkovic A, Garcia M, Laguno M, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM. Biglia A, et al. Among authors: blanco jl. Clin Infect Dis. 2004 Nov 15;39(10):1514-9. doi: 10.1086/425363. Epub 2004 Oct 25. Clin Infect Dis. 2004. PMID: 15546089

7

[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].

Laguno M, Sánchez-Tapias JM, Murillas J, Forns X, Blanco JL, Martínez E, Larrousse M, León A, Loncá M, Milinkovic A, Miró JM, García F, Gatell JM, Mallolas J. Laguno M, et al. Among authors: blanco jl. Enferm Infecc Microbiol Clin. 2005 Jan;23(1):32-40. doi: 10.1157/13070408. Enferm Infecc Microbiol Clin. 2005. PMID: 15701331 Review. Spanish.

8

Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.

Blanco JL, Biglia MA, Arnedo M, Martínez E, Mallolas J, Milinkovic A, Laguno M, Larrousse M, Leon A, Lonca M, García F, Miró JM, Pumarola T, Gatell JM. Blanco JL, et al. AIDS. 2005 May 20;19(8):829-31. doi: 10.1097/01.aids.0000168978.89961.22. AIDS. 2005. PMID: 15867498

9

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A. Ribera E, et al. Among authors: blanco jl. Antivir Ther. 2005;10(5):605-14. Antivir Ther. 2005. PMID: 16152754 Clinical Trial.

10

Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy.

Suy A, Martínez E, Coll O, Lonca M, Palacio M, de Lazzari E, Larrousse M, Milinkovic A, Hernández S, Blanco JL, Mallolas J, León A, Vanrell JA, Gatell JM. Suy A, et al. Among authors: blanco jl. AIDS. 2006 Jan 2;20(1):59-66. doi: 10.1097/01.aids.0000198090.70325.bd. AIDS. 2006. PMID: 16327320

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

343 results

Search Page

Filters